FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3110489661> ?p ?o ?g. }

• W3110489661 endingPage "320" @default.
• W3110489661 startingPage "314" @default.
• W3110489661 abstract "Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti-viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment response is yet unclear.To study the degree of on-treatment viral antigen decline among patients with pronounced HBV RNA decrease in relation to off-treatment sustained response and HBsAg loss.HBV RNA, HBsAg and hepatitis B core-related antigen (HBcrAg) were quantified in patients with chronic hepatitis B who participated in two randomised controlled trials of peginterferon-based therapy. Sustained response (HBV DNA <2000 IU/mL) and/or HBsAg loss were assessed in patients with and without on-treatment HBV RNA response (either >2 log HBV RNA decline or >1 log decline resulting in an undetectable value at on-treatment week 24), stratified by concomitant HBsAg decline (<0.5/0.5-1/>1 log).We enrolled 279 patients; 176 were hepatitis B e antigen (HBeAg)-positive, and 103 were HBeAg-negative. Sustained response was achieved in 20.4% of patients. At on-treatment week 24, HBV RNA response was associated with higher sustained response rates (27.4% vs 13.0% in non-responders, P = 0.004). However, among patients with an HBV RNA response (n = 135), 56.4% did not experience >0.5 log HBsAg decline. Among HBV RNA responders, sustained response was achieved in 47.6% of those with >1 log HBsAg decline (n = 20/42), vs 16.0% with <0.5 log decline (n = 12/75, P = 0.001). Similar results were obtained with HBcrAg and when response was defined as HBsAg loss.In this cohort, many patients with HBV RNA response during peginterferon-based treatment did not experience HBsAg and/or HBcrAg decline. The absence of concomitant decline in these viral antigens was associated with low rates of treatment response and HBsAg loss. Future trials should therefore consider kinetics of combined biomarkers to assess anti-viral efficacy. Trial registration, ClinicalTrials.gov: NCT00114361, NCT00146705." @default.
• W3110489661 created "2020-12-07" @default.
• W3110489661 creator A5000852072 @default.
• W3110489661 creator A5005200745 @default.
• W3110489661 creator A5011869728 @default.
• W3110489661 creator A5013918632 @default.
• W3110489661 creator A5018450847 @default.
• W3110489661 creator A5022452075 @default.
• W3110489661 creator A5031051209 @default.
• W3110489661 creator A5043626370 @default.
• W3110489661 creator A5063203259 @default.
• W3110489661 creator A5072894234 @default.
• W3110489661 creator A5082309779 @default.
• W3110489661 date "2020-11-21" @default.
• W3110489661 modified "2023-10-03" @default.
• W3110489661 title "Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss" @default.
• W3110489661 cites W1555699566 @default.
• W3110489661 cites W1987641812 @default.
• W3110489661 cites W2008517556 @default.
• W3110489661 cites W2026535163 @default.
• W3110489661 cites W2034076893 @default.
• W3110489661 cites W2046150771 @default.
• W3110489661 cites W2089153567 @default.
• W3110489661 cites W2101032357 @default.
• W3110489661 cites W2208817615 @default.
• W3110489661 cites W2237172879 @default.
• W3110489661 cites W2337051574 @default.
• W3110489661 cites W2413726467 @default.
• W3110489661 cites W2549013240 @default.
• W3110489661 cites W2768769427 @default.
• W3110489661 cites W2791328235 @default.
• W3110489661 cites W2792637331 @default.
• W3110489661 cites W2797479014 @default.
• W3110489661 cites W2802993478 @default.
• W3110489661 cites W2895729614 @default.
• W3110489661 cites W2907762216 @default.
• W3110489661 cites W2915431936 @default.
• W3110489661 cites W2945015734 @default.
• W3110489661 cites W2947049598 @default.
• W3110489661 cites W2947243310 @default.
• W3110489661 cites W2965330397 @default.
• W3110489661 cites W2983718038 @default.
• W3110489661 cites W2987458393 @default.
• W3110489661 cites W2988788411 @default.
• W3110489661 cites W2999514684 @default.
• W3110489661 cites W3006299716 @default.
• W3110489661 cites W3009378833 @default.
• W3110489661 cites W3110489661 @default.
• W3110489661 doi "https://doi.org/10.1111/apt.16172" @default.
• W3110489661 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7839551" @default.
• W3110489661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33222190" @default.
• W3110489661 hasPublicationYear "2020" @default.
• W3110489661 type Work @default.
• W3110489661 sameAs 3110489661 @default.
• W3110489661 citedByCount "9" @default.
• W3110489661 countsByYear W31104896612020 @default.
• W3110489661 countsByYear W31104896612021 @default.
• W3110489661 countsByYear W31104896612022 @default.
• W3110489661 countsByYear W31104896612023 @default.
• W3110489661 crossrefType "journal-article" @default.
• W3110489661 hasAuthorship W3110489661A5000852072 @default.
• W3110489661 hasAuthorship W3110489661A5005200745 @default.
• W3110489661 hasAuthorship W3110489661A5011869728 @default.
• W3110489661 hasAuthorship W3110489661A5013918632 @default.
• W3110489661 hasAuthorship W3110489661A5018450847 @default.
• W3110489661 hasAuthorship W3110489661A5022452075 @default.
• W3110489661 hasAuthorship W3110489661A5031051209 @default.
• W3110489661 hasAuthorship W3110489661A5043626370 @default.
• W3110489661 hasAuthorship W3110489661A5063203259 @default.
• W3110489661 hasAuthorship W3110489661A5072894234 @default.
• W3110489661 hasAuthorship W3110489661A5082309779 @default.
• W3110489661 hasBestOaLocation W31104896611 @default.
• W3110489661 hasConcept C126322002 @default.
• W3110489661 hasConcept C142462285 @default.
• W3110489661 hasConcept C147483822 @default.
• W3110489661 hasConcept C159047783 @default.
• W3110489661 hasConcept C203014093 @default.
• W3110489661 hasConcept C2522874641 @default.
• W3110489661 hasConcept C2775940106 @default.
• W3110489661 hasConcept C2777382497 @default.
• W3110489661 hasConcept C2777410769 @default.
• W3110489661 hasConcept C2779384505 @default.
• W3110489661 hasConcept C2780593183 @default.
• W3110489661 hasConcept C71924100 @default.
• W3110489661 hasConcept C90924648 @default.
• W3110489661 hasConceptScore W3110489661C126322002 @default.
• W3110489661 hasConceptScore W3110489661C142462285 @default.
• W3110489661 hasConceptScore W3110489661C147483822 @default.
• W3110489661 hasConceptScore W3110489661C159047783 @default.
• W3110489661 hasConceptScore W3110489661C203014093 @default.
• W3110489661 hasConceptScore W3110489661C2522874641 @default.
• W3110489661 hasConceptScore W3110489661C2775940106 @default.
• W3110489661 hasConceptScore W3110489661C2777382497 @default.
• W3110489661 hasConceptScore W3110489661C2777410769 @default.
• W3110489661 hasConceptScore W3110489661C2779384505 @default.
• W3110489661 hasConceptScore W3110489661C2780593183 @default.
• W3110489661 hasConceptScore W3110489661C71924100 @default.
• W3110489661 hasConceptScore W3110489661C90924648 @default.

• next